Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726037 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00726037 is a Phase 2 study that was terminated before completion, run by Loyola University. The registered enrollment target is 7 participants.
The verdict
NCT00726037, a Phase 2 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
Interventions
- DRUG Ontak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726037
The ClinicalTrials.gov registry entry for NCT00726037 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ontak is the first listed.
NCT00726037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726037 about?
NCT00726037 is a clinical study titled "A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer". This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
What is the current status of trial NCT00726037?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00726037?
The interventions under investigation include: Ontak (DRUG).
Who is sponsoring clinical trial NCT00726037?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.